Search research articles
Contact Us
Filters
Showing results (101-110 of 149) with videos related to
Page
of 15
Sort By:
Blood
|
September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
Fortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
British Journal of Haematology
|
April 26, 2002
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres
Livio Pagano, Luana Fianchi, Luca Mele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 16, 2014
Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia
Giampaolo Bucaneve, Alessandra Micozzi, Marco Picardi, et al.
Blood
|
January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Valeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
The Lancet. Oncology
|
November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
The Lancet. Oncology
|
November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Critical Reviews in Oncology/Hematology
|
November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
Mattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
Cancer
|
September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients
Alessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.
Cancers
|
November 13, 2025
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?
Sonia Morè, Massimo Offidani, Laura Corvatta, et al.
Cancers
|
February 13, 2025
Long-Term Survival with Multiple Myeloma: An Italian Experience
Francesca Fazio, Martina Gherardini, Elena Rossi, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 149) with videos related to
Sort By:
Page
of 15
Blood
|
September 29, 2011
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
Fortunato Morabito, Massimo Gentile, Carla Mazzone, et al.
British Journal of Haematology
|
April 26, 2002
Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres
Livio Pagano, Luana Fianchi, Luca Mele, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 16, 2014
Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia
Giampaolo Bucaneve, Alessandra Micozzi, Marco Picardi, et al.
Blood
|
January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma
Valeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
The Lancet. Oncology
|
November 25, 2015
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial
Francesca Gay, Stefania Oliva, Maria Teresa Petrucci, et al.
The Lancet. Oncology
|
November 14, 2021
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial
Francesca Gay, Pellegrino Musto, Delia Rota-Scalabrini, et al.
Critical Reviews in Oncology/Hematology
|
November 19, 2018
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials
Mattia D'Agostino, Lorenzo De Paoli, Concetta Conticello, et al.
Cancer
|
September 21, 2011
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients
Alessandro Gozzetti, Alfonso Cerase, Flavia Lotti, et al.
Cancers
|
November 13, 2025
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?
Sonia Morè, Massimo Offidani, Laura Corvatta, et al.
Cancers
|
February 13, 2025
Long-Term Survival with Multiple Myeloma: An Italian Experience
Francesca Fazio, Martina Gherardini, Elena Rossi, et al.
Page
of 15